34 results about "Vascular Calcifications" patented technology

The invention discloses an application of an RUNX2 inhibitor in preparation of a medicine for treating vascular calcification related diseases, and the RUNX2 inhibitor comprises an ester compound which is selected from at least one of Corilagin, 1, 2, 3, 6-tetragalloylglucose, NADP (Nicotinamide Adenine Dinucleotide Phosphate), Stafib-2 and uridine triphosphate sodium salt. The ester compound provided by the invention is used as a drug for inhibiting vascular calcification and progression of the RUNX2 inhibitor, and provides a new thought, a target spot and a small molecule drug for treatment of vascular calcification. The five small molecule compounds have good drug safety and a strong vascular calcification inhibition effect, and can be used as candidate drugs for inhibiting vascular calcification.

The invention belongs to the field of biological medicine, and particularly relates to application of deaminotyrosine in preparation of a medicine for treating vascular calcification symptoms. The invention finds that deaminotyrosine can significantly reduce the vascular calcification degree of an in-vitro cell model and an in-vivo animal model by inhibiting osteogenic differentiation and calcium salt deposition of vascular smooth muscle cells; therefore, the invention provides a new application of the deaminated tyrosine or pharmaceutically acceptable salt, ester, solvate or prodrug thereof in preparation of drugs for treating vascular calcification symptoms. The invention also provides a pharmaceutical composition, which takes deaminated tyrosine as an active component, and provides a brand new drug choice for clinical prevention and treatment of vascular calcification.

The invention provides application of retinoic acid in preparation of a medicine for treating vascular calcification, and belongs to the technical field of medicines. The early warning and treatment effects of retinoic acid on vascular calcification are provided for the first time, a new source is provided for preparing the medicine for early warning and / or treating vascular calcification, and meanwhile the new medicinal value of retinoic acid is explored. Cardiovascular calcification and vascular smooth muscle cell calcification are relieved by supplementing retinoic acid in vivo and in vitro, and the feasibility that retinoic acid can be used as a potential medicine for treating vascular calcification is prompted. The retinoic acid content is in negative correlation with the coronary artery calcification integral of the human body and the calcification severity degree, and it is prompted that the retinoic acid content can serve as an early warning index of cardiovascular calcification and the severity degree.

The invention discloses a vascular calcification dynamic monitoring method based on signal pattern recognition, and relates to the technical field of vascular mechanics signal analysis, and the method comprises the steps: obtaining acoustic original data of a target vascular region in a cardiac cycle, completing time synchronization and noise suppression based on a cardiac cycle starting point, and obtaining an acoustic data segment; constructing a displacement sequence changing along with time in the radial depth direction, and extracting amplitude, phase and deformation tracks to form a motion parameter set; arranging the motion parameters according to depths to construct a cardiac cycle response fingerprint matrix, and determining boundary positions of an intima, a middle membrane and an adventitia of a blood vessel wall according to motion mode differences of different depths; local offset features are collected and recognized based on multiple moments, the depth position of calcification in the blood vessel wall is determined, and dynamic monitoring of calcification along with time is achieved. According to the method, continuous presentation of the hierarchical structure of the blood vessel wall and fine expression of mechanical response of multiple layers of tissues are realized, and abnormal changes related to calcification can be sensitively recognized.

The application provides application of PCN in preparation of a drug for preventing and treating vascular calcification, belongs to the technical field of biological medicine, and further provides a drug for preventing or treating vascular calcification, wherein an effective component of the drug comprises PCN.The application applies PCN to treatment of vascular sclerosis, and can effectively improve vascular calcification and inhibit the development process of vascular calcification.

The invention discloses application of icariin in preparation of drugs for preventing and treating chronic kidney disease mineral substances and bone metabolism disorders. Relates to the technical field of medicine. The invention provides an application of icariin as an active pharmaceutical ingredient in preparation of a CKD-MBD treatment drug. Pharmacological experiments show that icariin can improve renal fibrosis, inhibit hyperparathyroidism, correct calcium and phosphorus metabolism, regulate and control bone metabolism related molecular expression, inhibit transdifferentiation of vascular smooth muscle cells to bone cells, inhibit vascular calcification and correct bone metabolism disorder, so that CKD-MBD is effectively prevented and treated. When icariin is used for preventing or treating CKD-MBD, the icariin is clear in component, exact in curative effect and low in side effect, and has a wide medical application prospect.

The invention relates to application of harmine in preparation of a medicine for preventing and treating vascular calcification. The harmine can be used for preventing and / or treating vascular calcification. Experiments show that harmine reduces osteogenic differentiation of vascular smooth muscle cells by down-regulating expression of RUNX2 and BMP2 and up-regulating expression of alpha-SMA at the same time, calcium salt deposition of blood vessels can be reduced, and it is indicated that harmine has a remarkable inhibition effect on vascular calcification. The new application of harmine in the anti-vascular calcification aspect is confirmed, so that the research of harmine in the technical field of medicines can be expanded, a new way is provided for research and development of drugs for treating vascular calcification, and a new theoretical direction is provided for clinical application.

The application relates to application of a medicine taking ACLY gene as an action target in preparation of a medicine for preventing and treating vascular calcification, and belongs to the technical field of biological medicine. In order to solve the problem that effective clinical means for treating vascular calcification is lacked at present, the application provides application of a medicine taking ACLY gene as an action target in preparation of a medicine for preventing and treating vascular calcification, the transcription or translation of the ACLY gene of vascular smooth muscle cells is efficiently and specifically inhibited, or the expression or activity of the ACLY protein of the vascular smooth muscle cells is efficiently and specifically reduced, the osteogenic differentiation of smooth muscle is reduced, the deposition of hydroxyapatite in the vascular media is reduced, and the progress of vascular calcification is alleviated. The medicine for preventing and treating vascular calcification is prepared on the basis of inhibition of the ACLY of vascular smooth muscle, has important clinical application potential for vascular calcification treatment, and can provide a new treatment option for patients with vascular calcification.

The invention provides application of a CXC chemokine ligand 13 as a vascular calcification diagnosis marker, and belongs to the technical field of medicines. The high expression of the CXCL13 prompts the high risk of vascular calcification, and the reagent for detecting the expression level of the CXC chemotactic factor ligand 13 can be used for preparing a vascular calcification early-warning reagent or early-warning kit. The invention studies the effect and molecular mechanism of CXCL13 in macrophages and vascular smooth muscle cells for regulating and controlling vascular calcification, provides an early intervention target for vascular calcification, and has great significance for early diagnosis and prevention of vascular calcification.

The invention belongs to the technical field of biological medicine and molecular biology, and particularly relates to application of LGR5 in diagnosis and treatment of vascular calcification. Experiments prove that the key effect of the LGR5 in aortic smooth muscle calcification is found for the first time, it is indicated that the LGR5 is a new target spot for regulating and controlling vascular calcification, meanwhile, vascular calcification can be accurately inhibited through knockdown / knockout of the specific Lgr5 gene of vascular smooth muscle, and meanwhile, vascular calcification can be accurately inhibited through knockout / knockout of the specific Lgr5 gene of the vascular smooth muscle. According to the application disclosed by the invention, the mechanism that the Lgr5 regulates and controls the osteogenic differentiation of the vascular smooth muscle cells through the Wnt / beta-catenin signal channel is preliminarily clarified, and a clear action target and a theoretical basis are provided for drug research and development; the invention provides a new strategy for treatment of diseases such as atherosclerosis and the like, and has a wide clinical application prospect.

The present invention relates to a composition for improving cardiovascular calcification using a mulberry tree extract and a method for preparing the same. The composition is prepared by collecting the fruit (mulberry), leaves (mulberry leaves), branches (mulberry branches), and root bark (mulberry bark) of the mulberry tree, extracting the fruit and freeze-drying it to produce a mulberry extract, hot-air drying the leaves, branches, and root bark, adding 20-70% ethanol corresponding to 5-50% by weight of each, extracting at 50-90°C for 2-10 hours, filtering and concentrating the extract, and freeze-drying the extract to obtain a mulberry tree extract, and dissolving each extract in distilled water at a concentration of 10-50 mg / ml to provide a composition for improving cardiovascular calcification using a mulberry tree extract and a method for preparing the same, thereby enabling relatively safe and effective improvement of cardiovascular calcification, including vascular calcification.

The application discloses a calcification elimination system for vascular calcification lesions, and relates to the technical field of medical calcification elimination devices, which comprises a multi-cavity catheter, an ultrasonic conducting wire and a filter screen. A broken balloon is arranged on the outer wall of the multi-cavity catheter. The multi-cavity catheter comprises a suction cavity, a first filling cavity, a conducting wire cavity and a wire-retracting cavity, which all extend along the length direction. A suction hole is arranged on the distal end side wall of the suction cavity. The ultrasonic conducting wire is partially arranged in the conducting wire cavity. The proximal end of the ultrasonic conducting wire is connected with an ultrasonic energy source. The ultrasonic conducting wire has a spiral section, which is sleeved on the outside of the broken balloon. The filter screen is located on the distal end side of the broken balloon. The filter screen is connected with the distal end wall of the suction cavity. The outer edge of the filter screen is connected with a wire-retracting wire. The proximal end of the wire-retracting wire extends to the proximal end of the multi-cavity catheter through the wire-retracting cavity. The application can completely break the plaque, ensures complete breaking of the plaque and improves the breaking efficiency. In addition, the application avoids the problem of vascular thermal damage caused by the local concentration of ultrasonic energy.

The invention relates to an interventional catheter system for vascular calcification treatment, which comprises an imaging positioning module, an interventional catheter, a local sealing unit, a therapeutic agent release unit and a control unit, and is characterized in that the system identifies and positions a vascular calcification focus in real time through the imaging module, and navigates the interventional catheter to the focus under the guidance of an image; a treatment cavity for temporarily blocking blood flow is formed through expansion of the local sealing unit, a treatment agent is accurately released in the cavity through the treatment agent release unit, and the control unit coordinates navigation, sealing and release operation of the whole process. A local static and visual precise treatment environment is constructed for calcification lesions in a continuous blood flow environment for the first time, and high-concentration enrichment and retention of a therapeutic agent at the lesions are achieved, so that the decalcification curative effect is remarkably improved, meanwhile, the drug action range is strictly limited, systemic exposure, hypocalcemia and other side effects are effectively avoided, and the treatment effect is good. And the treatment safety is greatly improved.

The application discloses a kind of based on photoacoustic viscoelasticity imaging's diabetic foot microvessel calcification evaluation system and method, the method includes: pulsed laser of laser is emitted by focusing objective lens, is irradiated on the foot surface tissue of diabetic patient and generates photoacoustic signal;Using phase-locked amplifier extraction photoacoustic signal's phase delay;Computer control motor scans foot surface tissue and saves photoacoustic signal data and photoacoustic signal's phase delay data.Photoacoustic signal is processed to extract the time width information of wave crest, the wave crest time width data of each point photoacoustic signal and phase delay data are respectively mapped to image in the form of gray value, and the image about the elasticity and viscoelasticity of diabetic foot surface tissue is reconstructed.Calcification threshold and inflammation threshold are set, and the imaging area is divided into different elastic regions using threshold segmentation method, and then the vascular calcification of diabetic foot is evaluated using viscoelasticity parameters, to detect whether there is calcification and inflammation in the microvessel of diabetic foot.

The invention discloses a multi-task joint segmentation method for kidney stone and vascular calcification in a coronary CTA image, and relates to the technical field of image segmentation processing, and the segmentation method comprises the following steps: obtaining coronary CTA image data, constructing a multi-task joint segmentation network, inputting the standardized image data into a shared feature encoder, and obtaining a shared feature encoder; and performing inter-task feature interaction enhancement on the multi-scale feature representation through a task interaction module to obtain enhanced feature representation, respectively inputting the enhanced feature representation into a kidney stone segmentation decoder and a vascular calcification segmentation decoder, and generating a final joint segmentation mask image according to a kidney stone segmentation result and a vascular calcification segmentation result. The method has the advantages that the segmentation of kidney stone and vascular calcification is completed in a single network at the same time through a multi-task joint learning framework, and compared with a scheme of independently training two models, the model complexity and computing resource consumption are reduced, and the feasibility of practical application is improved.

The invention discloses an expandable rotary cutting device for treating vascular calcification lesion, and relates to the technical field of medical instruments, the expandable rotary cutting device comprises a rotary cutting drill bit, a guide wire, a suction catheter, an optical fiber group, a saline infusion tube and a transmission shaft which are coaxially assembled, and the rotary cutting drill bit is provided with a guide wire hole, cutting teeth, an expandable blade, an expansion guide groove and a suction blade. By integrating multiple functions of plaque rotary cutting, active suction, saline irrigation and the like, most plaque types are solved, and compared with the tedious processes of replacing an expansion instrument after rotary cutting and removing chippings by depending on additional equipment in the prior art, the number of instrument exchange times is reduced, the operation time is shortened, and the operation efficiency is improved. Meanwhile, the vascular wall injury risk caused by repeated instrument access to the blood vessel is avoided.

Disclosed is a shock wave balloon for treating vascular calcification, comprising a shock wave balloon main body (1). The interior of the shock wave balloon main body (1) is provided with a medical catheter (4), a circular sliding ring (7) is sleeved on a side surface of the shock wave balloon main body (1), and a rubber sliding column (18) is connected to the interior of the circular sliding ring (7) in a sliding manner. According to the contraction or expansion of a height-limiting moving ring (8), the height-limiting moving ring (8) may drive an adjustment and contraction sliding rod (16) to slide inside a contraction hollow sleeve (17), such that a position-limiting adjustment disk (20), a fixing block (21), and a height-limiting rod (22) can be driven to move. A wear-resistant stick (19) is pushed to extend through the contraction hollow sleeve (17) into the adjustment and contraction sliding rod (16) to fix an adjustment spacing between the position-limiting adjustment disk (20) and the height-limiting rod (22), such that the expansion diameter of the height-limiting moving ring (8) can be adjusted in advance, and an expansion range of the shock wave balloon main body (1) is adjusted, thereby preventing an excessively large expansion diameter of the shock wave balloon main body (1) from causing damage to blood vessels of a patient.

The application belongs to the technical field of medicine, and particularly relates to application of alpha-ketobutyric acid in preparation of a medicine for preventing and / or treating vascular calcification. Through a high-phosphorus-induced vascular smooth muscle cell calcification model and a vitamin D3-induced mouse aorta calcification model, the application first proves that alpha-ketobutyric acid can significantly inhibit vascular calcium salt deposition, reduce osteogenic-like transdifferentiation of vascular smooth muscle cells, and down-regulate expression of osteogenic-related markers such as RUNX2 and BMP2. In addition, alpha-ketobutyric acid and sodium hydrosulfide in combination show a synergistic effect. The application provides a new medicine selection and strategy for prevention and treatment of vascular calcification and related cardiovascular diseases.

The invention discloses an application of dihydrocapsaicin in treatment of vascular calcification. Specifically, the invention discloses application of dihydrocapsaicin or pharmaceutically acceptable salt thereof, the dihydrocapsaicin or the pharmaceutically acceptable salt thereof is used for preparing a preparation or a composition, and the preparation or the composition is used for treating vascular calcification. Particularly, calcification of vascular smooth muscle cells can be effectively treated.

The invention discloses application of a quasi-kinesization modification inhibitor in preparation of a medicine for preventing and / or treating vascular calcification of chronic kidney diseases. The micafungin serving as a metalloid modification inhibitor inhibits osteogenic transdifferentiation of vascular smooth muscle cells, reduces the expression of an osteogenic factor RUNX2 and increases the expression of a contraction marker alpha-SMA of the vascular smooth muscle cells. Meanwhile, calcium salt deposition of vascular smooth muscle cells is remarkably inhibited. It is found for the first time that micafungin can play a role in protecting CKD vascular calcification independent of the antifungal effect of micafungin. The discovery provides a new hope for prevention and treatment of CKD vascular calcification.

This invention relates to the pharmaceutical applications of HSPB6 in the prevention and treatment of vascular calcification, belonging to the field of biomedical technology. This invention is the first to demonstrate a significant negative correlation between HSPB6 expression levels and the progression of vascular calcification. HSPB6 overexpression can significantly inhibit osteogenic phenotype transformation of vascular smooth muscle cells, reduce in vitro and in vivo vascular calcium deposition, and delay the occurrence and development of vascular calcification. Based on this, this invention provides the application of HSPB6 expression level detection reagents in the preparation of auxiliary diagnostic products for vascular calcification, and the application of HSPB6-specific overexpression reagents in the preparation of drugs for the prevention and / or treatment of vascular calcification, providing new targets and strategies for the early diagnosis and targeted prevention and treatment of vascular calcification.

This invention discloses the application of limonene in the preparation of drugs for alleviating or improving vascular calcification. Intervention with limonene in CKD mouse models and primary vascular smooth muscle cells (VSMCs) significantly inhibited aortic calcification in CKD mice, significantly reduced high-phosphorus-induced osteogenic differentiation and calcium deposition in VSMCs, inhibited reactive oxygen species (ROS) production, reduced cellular iron accumulation, and alleviated ferroptosis. The findings of this application are highly likely to provide effective clinical drugs for the prevention and treatment of vascular calcification in CKD.

The present invention relates to a pharmaceutical composition comprising an autotaxin inhibitor as an active ingredient for preventing or treating calcification-related diseases. Specifically, the autotaxin inhibitor is useful for the prevention or treatment of calcification-related diseases such as vascular calcification, vascular stiffening, vascular inflammation, vascular fibrosis, vascular stenosis, valvular calcification, valvular inflammation, valvular fibrosis, aortic valve stenosis, and calcinosis cutis.

A catheter system for placement in a blood vessel having a vessel wall.SOLUTION: The catheter system includes a power source, a controller, and a light guide. The power source generates a plurality of energy pulses 342B. The controller controls the power source such that the plurality of energy pulses cooperate to produce a resultant energy pulse 348B having a resultant pulse shape. The light guide emits optical energy in a direction away from the light guide to generate a plasma pulse 346B away from the light guide. The power source may be a laser and the light guide may be an optical fiber. Each of the energy pulses 342B has a pulse width and are added together such that the combined energy pulse has a pulse width that is longer than the pulse width of any of the energy pulses. The at least two energy pulses can have the same wavelength or different wavelengths from each other.SELECTED DRAWING: Figure 3B

The invention relates to the technical field of biological medicine, and discloses application of a small molecule compound activating PIAS1 in preparation of a medicine for preventing and / or treating diabetic vascular calcification. The medicine disclosed by the invention can activate the activity of PIAS1 in a certain concentration range, so that the calcification of VSMCs is inhibited. The medicine can target PIAS1 to treat diabetic vascular calcification (DVC), and can also be applied to early prevention of DVC.

The present application relates to the application of QKI gene in the preparation of drugs for preventing and treating vascular calcification. The present application discloses the important role of QKI gene in regulating vascular calcification by constructing smooth muscle specific QKI knockout mice. Compared with the control mice, the QKI knockout mice significantly reduce the occurrence of vascular calcification, including the decrease of Runx2 gene expression level, the significant reduction of vascular calcium salt deposition and the decrease of vascular tissue calcium ion. In the in vitro test, it is found that QKI siRNA makes the alizarin red staining of mouse vascular smooth muscle cells under high phosphorus stimulation weaken, the calcium content decreases, and the vascular smooth muscle cell calcification is reduced. It is found that the present application takes QKI gene as the action target to prepare or screen the drug for slowing down the vascular calcification, and the drug has important significance in the treatment of vascular calcification.

The invention provides a vascular calcification ablation catheter and a vascular calcification ablation system. The vascular calcification ablation catheter comprises a catheter body, a real-time ultrasonic image module and a directional ablation module. The real-time ultrasonic image module and the directional ablation module are respectively arranged on the catheter main body and are used for intervening in a blood vessel along with the catheter main body; wherein the real-time ultrasonic image module is used for acquiring real-time ultrasonic image information of a blood vessel target area; and the directional ablation module is configured to directionally emit ablation energy to a calcification target spot of the blood vessel target area based on the real-time ultrasonic image information. According to the configuration, the real-time ultrasonic image information of the blood vessel target area is obtained through the real-time ultrasonic image module, then the directional ablation module is used for directionally sending out ablation energy based on the real-time ultrasonic image information, diagnosis and directional ablation can be integrated, and the space registration error and time delay of the mode that treatment is conducted after scanning diagnosis are effectively overcome.

The utility model provides a kind of catheter assembly and medical equipment.Catheter assembly includes first tube body and shock wave generation component.First tube body is formed with first accommodating cavity.Shock wave generation component includes at least two discharge parts, at least two discharge parts are spaced apart and set to the distal end in first accommodating cavity along the length direction of first tube body, at least two adjacent discharge parts form discharge region, to produce shock wave in liquid medium in first accommodating cavity.Wherein, discharge region is parallel to the central axis of first tube body, and at least part discharge region and the central axis of first tube body are overlapped.Such ensure that catheter assembly can have smaller size in radial direction, effectively improve the practicability of catheter assembly.In the treatment of blood vessel calcification lesion using catheter assembly, catheter assembly can directly pass through relatively narrow lesion site, effectively simplify the treatment step, reduce the cost required for treatment, and improve the experience of patient use.

The invention discloses an astaxanthin composition, an oral delivery system and application thereof, and relates to the technical field of drug delivery. The astaxanthin composition comprises the following raw materials: fatty acid, a foaming agent, weak organic acid and astaxanthin, fatty acid is selected from at least one of capric acid, caprylic acid and linoleic acid; the foaming agent is selected from at least one of sodium bicarbonate, potassium carbonate and potassium bitartrate; the weak organic acid is selected from at least one of citric acid, malic acid and tartaric acid. Through verification, the astaxanthin composition provided by the invention is coated by an enteric-coated material, and can relieve the thickening of vascular walls and improve angiosclerosis after being orally taken. Good application prospects are realized on prevention or treatment of vascular calcification and complications thereof.

Disclosed is a shock wave therapeutic instrument for treating vascular calcification, comprising a box body (1) and electronic components mounted on an inner wall of the box body (1). An upper surface of the box body (1) is fixedly connected to a machine body (2), and a side surface of the box body (1) is provided with a connection wire (7). One end of the connection wire (7) away from the box body (1) is fixedly connected to a shock wave therapeutic instrument (6). The shock wave therapeutic instrument (6) can extend into an interior of an extension tube (3), and a push rod (13) is pushed downward such that the push rod (13) can drive a wiping seat (14) downward. A top end of the shock wave therapeutic instrument (6) can extend into an interior of the wiping seat (14), and the push rod (13) is rotated such that the push rod can drive the wiping seat (14) to rotate. By means of the rotation of the wiping seat (14), a wiping ball (18), a limiting seat (15), a wiping cloth (17), and a cloth strip (16) are caused to rotate together, such that the cleaning quality of the shock wave therapeutic instrument (6) can be improved.